Targeting cancer vulnerabilities with high-dose vitamin C

Article metrics


Over the past century, the notion that vitamin C can be used to treat cancer has generated much controversy. However, new knowledge regarding the pharmacokinetic properties of vitamin C and recent high-profile preclinical studies have revived interest in the utilization of high-dose vitamin C for cancer treatment. Studies have shown that pharmacological vitamin C targets many of the mechanisms that cancer cells utilize for their survival and growth. In this Opinion article, we discuss how vitamin C can target three vulnerabilities many cancer cells share: redox imbalance, epigenetic reprogramming and oxygen-sensing regulation. Although the mechanisms and predictive biomarkers that we discuss need to be validated in well-controlled clinical trials, these new discoveries regarding the anticancer properties of vitamin C are promising to help identify patient populations that may benefit the most from high-dose vitamin C therapy, developing effective combination strategies and improving the overall design of future vitamin C clinical trials for various types of cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Integrated pro-oxidant mechanism of vitamin C and cancer cell cytotoxicity.
Fig. 2: Regulation of TET enzymes by ascorbate.
Fig. 3: Ascorbate and HIF1α regulation.


  1. 1.

    Strebhardt, K. & Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473–480 (2008).

  2. 2.

    Levine, M., Padayatty, S. J. & Espey, M. G. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv. Nutr. 2, 78–88 (2011).

  3. 3.

    Nauman, G. et al. Systematic review of intravenous ascorbate in cancer clinical trials. Antioxidants 7, E89 (2018).

  4. 4.

    Padayatty, S. J. & Levine, M. Vitamin C: the known and the unknown and Goldilocks. Oral Dis. 22, 463–493 (2016).

  5. 5.

    Maeda, N. et al. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc. Natl Acad. Sci. USA 97, 841–846 (2000).

  6. 6.

    Corti, A., Casini, A. F. & Pompella, A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch. Biochem. Biophys. 500, 107–115 (2010).

  7. 7.

    Vera, J. C. et al. Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid. Blood 84, 1628–1634 (1994).

  8. 8.

    Wilson, J. X. The physiological role of dehydroascorbic acid. FEBS Lett. 527, 5–9 (2002).

  9. 9.

    Buettner, G. R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300, 535–543 (1993).

  10. 10.

    Lane, D. J. R. & Richardson, D. R. The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption! Free Radic. Biol. Med. 75, 69–83 (2014).

  11. 11.

    Kuiper, C. & Vissers, M. C. M. Ascorbate as a co-factor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front. Oncol. 4, 359 (2014).

  12. 12.

    Schieber, M. & Chandel, N. S. ROS function in redox signaling and oxidative stress. Curr. Biol. 24, R453–R462 (2014).

  13. 13.

    Chio, I. I. C. & Tuveson, D. A. ROS in cancer: the burning question. Trends Mol. Med. 23, 411–429 (2017).

  14. 14.

    Sayin, V. I. et al. Antioxidants accelerate lung cancer progression in mice. Sci. Transl Med. 6, 221ra15 (2014). This study demonstrates that dietary supplementation of antioxidants ( N -acetylcysteine and vitamin E) markedly increases tumour progression and reduces survival in mouse models of KRAS-induced or BRAF-induced lung cancer.

  15. 15.

    Le Gal, K. et al. Antioxidants can increase melanoma metastasis in mice. Sci. Transl Med. 7, 308re8 (2015).

  16. 16.

    Piskounova, E. et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186–191 (2015).

  17. 17.

    Klein, E. A. et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 306, 1549–1556 (2011).

  18. 18.

    Omenn, G. S. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150–1155 (1996).

  19. 19.

    Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330, 1029–1035 (1994).

  20. 20.

    Wondrak, G. T. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid. Redox Signal. 11, 3013–3069 (2009).

  21. 21.

    Torti, S. V. & Torti, F. M. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13, 342–355 (2013).

  22. 22.

    DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).

  23. 23.

    Manz, D. H. et al. Iron and cancer: recent insights. Ann. NY Acad. Sci. 1368, 149–161 (2016).

  24. 24.

    Hentze, M. W. et al. Two to tango: regulation of mammalian iron metabolism. Cell 142, 24–38 (2010).

  25. 25.

    Du, J., Cullen, J. J. & Buettner, G. R. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta 1826, 443–457 (2012).

  26. 26.

    Chen, Q. et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl Acad. Sci. USA 102, 13604–13609 (2005).

  27. 27.

    Du, J. et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res. 16, 509–520 (2010).

  28. 28.

    Rawal, M. et al. Manganoporphyrins increase ascorbate-induced cytotoxicity by enhancing H2O2 generation. Cancer Res. 73, 5232–5241 (2013).

  29. 29.

    Duarte, T. L., Almeida, G. M. & Jones, G. D. D. Investigation of the role of extracellular H2O2 and transition metal ions in the genotoxic action of ascorbic acid in cell culture models. Toxicol. Lett. 170, 57–65 (2007).

  30. 30.

    Sakagami, H. et al. Effect on an iron-chelator on ascorbate-induced cytotoxicity. Free Radic. Biol. Med. 23, 260–270 (1997).

  31. 31.

    Buettner, G. R. & Jurkiewicz, B. A. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat. Res. 145, 532–541 (1996).

  32. 32.

    Clément, M. V. et al. The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid. Redox Signal. 3, 157–163 (2001).

  33. 33.

    Carr, A. & Frei, B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J. 13, 1007–1024 (1999).

  34. 34.

    Halliwell, B. Vitamin C: antioxidant or pro-oxidant in vivo? Free Radic. Res. 25, 439–454 (1996).

  35. 35.

    Chen, Q. et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl Acad. Sci. USA 104, 8749–8754 (2007). This study shows that pharmacological ascorbate is a prodrug for preferential steady-state formation of Asc •− and H2O2 in the extracellular space but not in the blood in vivo system.

  36. 36.

    Ma, E. et al. Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. Free Radic. Biol. Med. 113, 36–47 (2017).

  37. 37.

    Rychtarcikova, Z. et al. Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. Oncotarget 8, 6376–6398 (2017).

  38. 38.

    Kiessling, M. K. et al. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T cell lymphoma. Cancer Res. 69, 2365–2374 (2009).

  39. 39.

    Pinnix, Z. K. et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl Med. 2, 43ra56 (2010).

  40. 40.

    Corna, G. et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 95, 1814–1822 (2010).

  41. 41.

    Recalcati, S. et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur. J. Immunol. 40, 824–835 (2010).

  42. 42.

    Panis, C. et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res. Treat. 133, 881–888 (2012).

  43. 43.

    Schoenfeld, J. D. et al. O2 •− and H2O2 mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell 31, 487–500 (2017). This study shows that pharmacological ascorbate selectively sensitizes non-small-cell lung cancer (NSCLC) and glioblastoma (GBM) cells by generating redox-active labile iron and H 2O2 using in vitro cell lines and mouse models. In addition, it shows the potential efficacy of ascorbate therapy combined with other chemotherapies in patients with GBM and NSCLC.

  44. 44.

    Xia, J. et al. Multiple myeloma tumor cells are selectively killed by pharmacologically-dosed ascorbic acid. EBioMedicine 18, 41–49 (2017).

  45. 45.

    Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211–218 (2016).

  46. 46.

    Yun, J. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555–1559 (2009).

  47. 47.

    Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391–1396 (2015). This study demonstrates that uptake of DHA by GLUT1, and its subsequent reduction to ascorbate, depletes essential antioxidants to induce cell death in KRAS or BRAF mutant CRC cells.

  48. 48.

    Nualart, F. J. et al. Recycling of vitamin C by a bystander effect. J. Biol. Chem. 278, 10128–10133 (2003).

  49. 49.

    May, J. M. et al. Ascorbate recycling in human erythrocytes: role of GSH in reducing dehydroascorbate. Free Radic. Biol. Med. 20, 543–551 (1996).

  50. 50.

    Tu, H. et al. Chemical transport knockout for oxidized vitamin C, dehydroascorbic acid, reveals its functions in vivo. EBioMedicine 23, 125–135 (2017).

  51. 51.

    Lu, Y.-X. et al. Pharmacological ascorbate suppresses growth of gastric cancer cells with GLUT1 overexpression and enhances the efficacy of oxaliplatin through redox modulation. Theranostics 8, 1312–1326 (2018).

  52. 52.

    Tian, W. et al. The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C-induced toxicity. J. Biol. Chem. 289, 3339–3351 (2014).

  53. 53.

    Vera, J. C. et al. Resolution of the facilitated transport of dehydroascorbic acid from its intracellular accumulation as ascorbic acid. J. Biol. Chem. 270, 23706–23712 (1995).

  54. 54.

    Szatrowski, T. P. & Nathan, C. F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51, 794–798 (1991).

  55. 55.

    Policastro, L. L. et al. The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. Antioxid. Redox Signal. 19, 854–895 (2013).

  56. 56.

    Rees, D. C., Kelsey, H. & Richards, J. D. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306, 841–842 (1993).

  57. 57.

    Quinn, J. et al. Effect of high-dose vitamin C infusion in a glucose-6-phosphate dehydrogenase-deficient patient. Case Rep. Med. 2017, 5202606 (2017).

  58. 58.

    Rakitzis, E. T. & Papandreou, P. T. Ascorbate-induced generation of free radical species in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. Biochem. Soc. Trans. 17, 371–372 (1989).

  59. 59.

    Mehta, J., Singhal, S. & Mehta, B. Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 336, 944 (1990).

  60. 60.

    Gaetani, G. F. et al. Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood 87, 1595–1599 (1996).

  61. 61.

    May, J. M., Qu, Z. & Morrow, J. D. Mechanisms of ascorbic acid recycling in human erythrocytes. Biochim. Biophys. Acta 1528, 159–166 (2001).

  62. 62.

    Yun, J. et al. Interactions between epigenetics and metabolism in cancers. Front. Oncol. 2, 163 (2012).

  63. 63.

    Rasmussen, K. D. & Helin, K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 30, 733–750 (2016).

  64. 64.

    Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).

  65. 65.

    Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).

  66. 66.

    Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).

  67. 67.

    Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170, 1079–1095 (2017). Using genetic mouse models of leukaemia, vitamin C is shown to enhance TET2 activity, increase DNA demethylation and suppress leukaemia progression.

  68. 68.

    Mingay, M. et al. Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia. Leukemia 32, 11–20 (2018).

  69. 69.

    Shenoy, N. et al. Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J. 7, e587 (2017).

  70. 70.

    Gustafson, C. B. et al. Epigenetic reprogramming of melanoma cells by vitamin C treatment. Clin. Epigenetics 7, 51 (2015).

  71. 71.

    Peng, D. et al. Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer. Clin. Epigenetics 10, 94 (2018).

  72. 72.

    Agathocleous, M. et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549, 476–481 (2017). Using various GEMMs, including GULO-knockout mice, this study reveals that vitamin C is necessary for normal haematopoietic stem cell development and the prevention of leukaemia in mice.

  73. 73.

    Monfort, A. & Wutz, A. Breathing-in epigenetic change with vitamin C. EMBO Rep. 14, 337–346 (2013).

  74. 74.

    Fedeles, B. I. et al. The AlkB family of Fe(II)/α-ketoglutarate-dependent dioxygenases: repairing nucleic acid alkylation damage and beyond. J. Biol. Chem. 290, 20734–20742 (2015).

  75. 75.

    Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721–732 (2003).

  76. 76.

    Koivunen, P. et al. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279, 9899–9904 (2004).

  77. 77.

    Vissers, M. C. M. & Das, A. B. Potential mechanisms of action for vitamin C in cancer: reviewing the evidence. Front. Physiol. 9, 809 (2018).

  78. 78.

    Wilkes, J. G. et al. Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1α (HIF-1α) in pancreatic adenocarcinoma. Clin. Exp. Metastasis 35, 37–51 (2018).

  79. 79.

    Gao, P. et al. HIF-dependent anti-tumorigenic effect of anti-oxidants in vivo. Cancer Cell 12, 230–238 (2007).

  80. 80.

    Józwiak, P. et al. Expression of hypoxia inducible factor 1α and 2α and its association with vitamin C level in thyroid lesions. J. Biomed. Sci. 24, 83 (2017).

  81. 81.

    Campbell, E. J. et al. Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo(−/−) mice. Cancer Med. 4, 303–314 (2015).

  82. 82.

    Campbell, E. J., Vissers, M. C. & Dachs, G. U. Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo−/− mice. Hypoxia 4, 41–52 (2016).

  83. 83.

    Campbell, E. J. et al. Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. Free Radic. Biol. Med. 99, 451–462 (2016).

  84. 84.

    Kuiper, C. et al. Increased tumor ascorbate is associated with extended disease-free survival and decreased hypoxia-inducible factor-1 activation in human colorectal cancer. Front. Oncol. 4, 10 (2014).

  85. 85.

    Wohlrab, C. et al. The association between ascorbate and the hypoxia-inducible factors in human renal cell carcinoma requires a functional Von Hippel-Lindau protein. Front. Oncol. 8, 574 (2018).

  86. 86.

    Kuiper, C. et al. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res. 70, 5749–5758 (2010).

  87. 87.

    King, A., Selak, M. A. & Gottlieb, E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25, 4675–4682 (2006).

  88. 88.

    Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77–85 (2005).

  89. 89.

    Koivunen, P. et al. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem. 282, 4524–4532 (2007).

  90. 90.

    Gill, A. J. et al. Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N. Engl. J. Med. 364, 885–886 (2011).

  91. 91.

    Pasini, B. & Stratakis, C. A. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J. Intern. Med. 266, 19–42 (2009).

  92. 92.

    Clark, G. R. et al. Germline FH mutations presenting with pheochromocytoma. J. Clin. Endocrinol. Metab. 99, E2046–E2050 (2014).

  93. 93.

    Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc. Natl Acad. Sci. USA 73, 3685–3689 (1976). This study is the first large-scale clinical trial designed to analyse the efficacy of high-dose ascorbate for the treatment of cancer.

  94. 94.

    Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl Acad. Sci. USA 75, 4538–4542 (1978).

  95. 95.

    Creagan, E. T. et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N. Engl. J. Med. 301, 687–690 (1979). This large-scale clinical trial shows that daily oral intake of high-dose vitamin C had no therapeutic benefit in patients with cancer.

  96. 96.

    Moertel, C. G. et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N. Engl. J. Med. 312, 137–141 (1985).

  97. 97.

    Padayatty, S. J. et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med. 140, 533–537 (2004). This paper emphasizes the importance of the route of administration of vitamin C and explains why two early clinical trials of vitamin C as an anticancer therapy had conflicting results.

  98. 98.

    Hoffer, L. J. et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann. Oncol. 19, 1969–1974 (2008).

  99. 99.

    Klimant, E. et al. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Curr. Oncol. 25, 139–148 (2018).

  100. 100.

    Carr, A. C. & Cook, J. Intravenous vitamin C for cancer therapy — identifying the current gaps in our knowledge. Front. Physiol. 9, 1182 (2018).

  101. 101.

    Kuiper, C., Vissers, M. C. M. & Hicks, K. O. Pharmacokinetic modeling of ascorbate diffusion through normal and tumor tissue. Free Radic. Biol. Med. 77, 340–352 (2014).

  102. 102.

    Cao, D. et al. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 9, 432 (2009).

  103. 103.

    Tian, Y. et al. Association of TET1 expression with colorectal cancer progression. Scand. J. Gastroenterol. 52, 312–320 (2017).

  104. 104.

    Mustafi, S. et al. Vitamin C sensitizes melanoma to BET inhibitors. Cancer Res. 78, 572–583 (2018).

  105. 105.

    Du, J. et al. Pharmacological ascorbate radiosensitizes pancreatic cancer. Cancer Res. 75, 3314–3326 (2015).

  106. 106.

    Liu, M. et al. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proc. Natl Acad. Sci. USA 113, 10238–10244 (2016).

  107. 107.

    Zhao, H. et al. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk. Res. 66, 1–7 (2018).

  108. 108.

    Gillberg, L. et al. Vitamin C — a new player in regulation of the cancer epigenome. Semin. Cancer Biol. 51, 59–67 (2017).

  109. 109.

    Carr, A. C. & Maggini, S. Vitamin C and immune function. Nutrients 9, 1211 (2017).

  110. 110.

    Sorice, A. et al. Ascorbic acid: its role in immune system and chronic inflammation diseases. Mini Rev. Med. Chem. 14, 444–452 (2014).

  111. 111.

    Ang, A. et al. Vitamin C and immune cell function in inflammation and cancer. Biochem. Soc. Trans. 46, 1147–1159 (2018).

  112. 112.

    Hausinger, R. P. FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes. Crit. Rev. Biochem. Mol. Biol. 39, 21–68 (2004).

  113. 113.

    Kersten, K. et al. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 9, 137–153 (2017).

  114. 114.

    Ma, Y. et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci. Transl Med. 6, 222ra18 (2014). This paper shows in its preclinical and clinical studies that high-dose vitamin C can potentially increase the efficacy and reduce the toxicities of certain conventional chemotherapies when used in combination to treat patients with ovarian cancer.

  115. 115.

    May, J. M. The SLC23 family of ascorbate transporters: ensuring that you get and keep your daily dose of vitamin C. Br. J. Pharmacol. 164, 1793–1801 (2011).

  116. 116.

    Corpe, C. P. et al. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J. Clin. Invest. 120, 1069–1083 (2010).

  117. 117.

    Sotiriou, S. et al. Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat. Med. 8, 514–517 (2002).

  118. 118.

    Vera, J. C. et al. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 364, 79–82 (1993).

  119. 119.

    Spielholz, C. et al. Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. Cancer Res. 57, 2529–2537 (1997).

  120. 120.

    Agus, D. B., Vera, J. C. & Golde, D. W. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 59, 4555–4558 (1999).

  121. 121.

    Mayland, C. R., Bennett, M. I. & Allan, K. Vitamin C deficiency in cancer patients. Palliat. Med. 19, 17–20 (2005).

  122. 122.

    Anthony, H. M. & Schorah, C. J. Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br. J. Cancer 46, 354–367 (1982).

  123. 123.

    Ullah, M. F. et al. Ascorbic acid in cancer chemoprevention: translational perspectives and efficacy. Curr. Drug Targets 13, 1757–1771 (2012).

  124. 124.

    Lee, K. W. et al. Vitamin C and cancer chemoprevention: reappraisal. Am. J. Clin. Nutr. 78, 1074–1078 (2003).

  125. 125.

    Khaw, K. T. et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 357, 657–663 (2001).

  126. 126.

    Luo, J., Shen, L. & Zheng, D. Association between vitamin C intake and lung cancer: a dose-response meta-analysis. Sci. Rep. 4, 6161 (2014).

  127. 127.

    Harris, H. R., Orsini, N. & Wolk, A. Vitamin C and survival among women with breast cancer: a meta-analysis. Eur. J. Cancer 50, 1223–1231 (2014).

  128. 128.

    Harris, H. R., Bergkvist, L. & Wolk, A. Vitamin C intake and breast cancer mortality in a cohort of Swedish women. Br. J. Cancer 109, 257–264 (2013).

  129. 129.

    Wohlrab, C., Phillips, E. & Dachs, G. U. Vitamin C transporters in cancer: current understanding and gaps in knowledge. Front. Oncol. 7, 74 (2017).

  130. 130.

    Michels, A. J., Hagen, T. M. & Frei, B. Human genetic variation influences vitamin C homeostasis by altering vitamin C transport and antioxidant enzyme function. Annu. Rev. Nutr. 33, 45–70 (2013).

  131. 131.

    Savini, I. et al. SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids 34, 347–355 (2008).

  132. 132.

    Wright, M. E. et al. Genetic variation in sodium-dependent ascorbic acid transporters and risk of gastric cancer in Poland. Eur. J. Cancer 45, 1824–1830 (2009).

  133. 133.

    Casabonne, D. et al. Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia. Eur. J. Nutr. 56, 1123–1133 (2017).

  134. 134.

    Duell, E. J. et al. Vitamin C transporter gene (SLC23A1 and SLC23A2) polymorphisms, plasma vitamin C levels, and gastric cancer risk in the EPIC cohort. Genes Nutr. 8, 549–560 (2013).

  135. 135.

    Mastrangelo, D. et al. Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation. Blood Cells. Mol. Dis. 69, 57–64 (2018).

  136. 136.

    Bienert, G. P. & Chaumont, F. Aquaporin-facilitated transmembrane diffusion of hydrogen peroxide. Biochim. Biophys. Acta 1840, 1596–1604 (2014).

  137. 137.

    Uetaki, M. et al. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci. Rep. 5, 13896 (2015).

  138. 138.

    Li, R. Vitamin C, a multi-tasking molecule, finds a molecular target in killing cancer cells. React. Oxyg. Species 1, 141–156 (2016).

  139. 139.

    Young, J. I., Züchner, S. & Wang, G. Regulation of the epigenome by vitamin C. Annu. Rev. Nutr. 35, 545–564 (2015).

  140. 140.

    Camarena, V. & Wang, G. The epigenetic role of vitamin C in health and disease. Cell. Mol. Life Sci. 73, 1645–1658 (2016).

  141. 141.

    Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8, 705–713 (2008).

  142. 142.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01852890 (2018).

  143. 143.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01752491 (2018).

  144. 144.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03797443 (2019).

  145. 145.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03410030 (2019).

  146. 146.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02420314 (2019).

  147. 147.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03613727 (2018).

  148. 148.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02344355 (2018).

  149. 149.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03146962 (2018).

  150. 150.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02905591 (2018).

  151. 151.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02905578 (2018).

  152. 152.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02516670 (2019).

  153. 153.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03334409 (2019).

  154. 154.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03418038 (2018).

  155. 155.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03015675 (2017).

  156. 156.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02969681 (2019).

Download references


The authors thank S. Wang in the Yun laboratory for helpful discussions and proofreading of the manuscript. The authors apologize for any references left uncited owing to space limitations. This work was supported by the US National Institutes of Health (NIH) grant R35 CA197588 (L.C.C.), Stand Up to Cancer–American Association for Cancer Research grant SU2C-AACR-DT22-17 (L.C.C.), the Cancer Prevention and Research Institute of Texas (CPRIT) grant RR170039 (J.Y.), the US National Cancer Institute (NCI) grant 1K22CA216036 (J.Y.), the US National Science Foundation Graduate Research Fellowship Program grant DGE1257284 (B.N.) and NCI grant 1F99CA234950-01 (B.N.). L.C.C. is a founder and member of the senior advisory boards of Agios Pharmaceuticals and Petra Pharmaceuticals, which are developing novel therapies for cancer. The L.C.C. laboratory also receives financial support from Petra Pharmaceuticals.

Reviewer information

Nature Reviews Cancer thanks J. Cullen, G. Dachs and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

L.C.C. and J.Y. contributed to the discussion of content of the article. J.Y. and B.N. researched data for the article. J.Y. and B.N. wrote the article. All authors reviewed and edited the manuscript before submission.

Correspondence to Lewis C. Cantley or Jihye Yun.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


2-Phosphate l-ascorbic acid

A derivative of ascorbate that is not oxidized in culture or serum but releases ascorbate once it is inside the cells via hydrolysis mediated by alkaline phosphatase on the plasma membrane.

5-Aza-CdR (decitabine)

A cytidine antimetabolite analogue that incorporates into DNA and inhibits DNA methyltransferase (DNMT) activity, which results in DNA demethylation (hypomethylation).


Any biological measurable indicators of the severity or presence of some disease state.

Fenton reaction

A chemical reaction that converts hydrogen peroxide into a highly toxic hydroxyl radical in the presence of labile iron.


A protein that contains iron and is the primary form of iron stored inside of cells.

Free radicals

Molecules possessing unpaired electrons and thus are reactive and short-lived in a biological setting.


An iron-containing group that gives myoglobin and haemoglobin the ability to bind oxygen.

Hydroxyl radical

(OH). A highly reactive and short-lived radical that attacks any molecule in its immediate vicinity, especially DNA, protein and lipids, eventually leading to cell death.


A BCR-ABL-selective tyrosine kinase inhibitor, also known as Gleevec. Imatinib has been used to treat chronic myelogenous leukaemia and acute lymphocytic leukaemia.

Intraperitoneal (IP) injection

Giving medicines or fluids into the peritoneum (body cavity), which is more often applied to animals than to humans.

Intravenous injection

Giving medicines or fluids through a needle or tube inserted into a vein, allowing them to enter the bloodstream immediately.

Michaelis constant

(Km). The substrate concentration at the half of the maximum velocity (Vmax). An enzyme with a high Km has a low affinity for its substrate and requires a greater concentration of substrate to achieve Vmax.

Parenteral injection

Giving medicine or fluids intravenously (into a vein), subcutaneously (under the skin) and intraperitoneally (into the peritoneum).


The study of the biochemical and physiological effects of drugs. Generally refers to the dose–response relationship for a particular drug.


The activity of drugs in the body over a period, including the processes by which drugs are absorbed, distributed in the body, localized in the tissues and excreted.

Pharmacological ascorbate

Intravenous or intraperitoneal delivery of vitamin C, which allows for plasma concentrations to reach the millimolar scale.

Physiological ascorbate

An oral dose of dietary vitamin C, usually resulting in a peak plasma concentration of 200 μM.

Predictive biomarkers

A biomarker that gives information about the effect of a therapeutic intervention.


A group that is a tightly bound, specific non-polypeptide unit required for the biological function of some proteins. It may be organic or inorganic (such as a metal ion), but not amino acids.

Randomized controlled trials

(RCTs). A study design that randomly assigns participants into an experimental group or a control group (or placebo group).

Reactive oxygen species

(ROS). Derivatives of oxygen that are more reactive than molecular oxygen.

Single-nucleotide polymorphisms

(SNPs). A variation in a single nucleotide that occurs at a specific position in the genome, where each variation is present to some high degree within a population (for example, >1%).

Therapeutic window

The range of doses of a drug that can treat disease effectively without having toxic effects.


(Tf). The main protein in the blood that binds to iron and transports it throughout the body.


A selective V600E mutant BRAF kinase inhibitor, also known as PLX4032. It has been used to treat BRAF V600E mutant melanoma.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading